Skip to main
VSTM

Verastem (VSTM) Stock Forecast & Price Target

Verastem (VSTM) Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 60%
Buy 40%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Verastem is a biopharmaceutical company in late-stage development with a promising pipeline and multiple drugs in various stages of development, including daraxonrasib, VS-7375, and a KRASG12D inhibitor. The company has also reported success with current treatments, mFOLFIRINOX and NALIRIFOX, and potential for partnerships in the EU. With a strong focus on low-grade serous ovarian cancer and projected peak sales of $292M, Verastem shows great potential for growth in the cancer treatment market.

Bears say

Verastem is relying on significant collaborations for the commercialization of its pipeline products with projected peak sales of $1.4B. However, the company's heavy safety profile raises concerns about the tolerability of these products. In addition, while some combination therapies have shown promising response rates, the DCR remains stagnant, indicating limited effectiveness. Despite advancements in late-stage trials, the company's reliance on partnerships makes it vulnerable to delays or setbacks in commercialization, potentially hindering its potential for growth.

Verastem (VSTM) has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 60% of analysts recommend a Strong Buy, 40% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Verastem and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Verastem (VSTM) Forecast

Analysts have given Verastem (VSTM) a Strong Buy based on their latest research and market trends.

According to 5 analysts, Verastem (VSTM) has a Strong Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $14.20, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $14.20, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Verastem (VSTM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.